Natural Killer(NK) Cell Therapy for AML Minimal Residual Disease
Status:
Recruiting
Trial end date:
2025-10-21
Target enrollment:
Participant gender:
Summary
This is an open-label, Phase I study of QN-030a (allogeneic NK cell therapy) in Acute Myeloid
Leukemia Minimal Residual Disease(AML MRD).
This clinical study is to evaluate the safety, tolerability and preliminary efficacy of
QN-020a in patients with AML MRD, where a "3+3" enrollment schema will be utilized at dose
escalation stage. Up to 18 patients will be enrolled.